title: Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells.
abstract: Activation of A2A adenosine receptors (A2ARs) protects kidneys from ischemia-reperfusion injury (IRI). A2ARs are expressed on bone marrow-derived (BM-derived) cells and renal smooth muscle, epithelial, and endothelial cells. To measure the contribution of A2ARs on BM-derived cells in suppressing renal IRI, we examined the effects of a selective agonist of A2ARs, ATL146e, in chimeric mice in which BM was ablated by lethal radiation and reconstituted with donor BM cells derived from GFP, A2AR-KO, or WT mice to produce GFP-->WT, A2A-KO-->WT, or WT-->WT mouse chimera. We found little or no repopulation of renal vascular endothelial cells by donor BM with or without renal IRI. ATL146e had no effect on IRI in A2A-KO mice or A2A-KO-->WT chimera, but reduced the rise in plasma creatinine from IRI by 75% in WT mice and by 60% in WT-->WT chimera. ATL146e reduced the induction of IL-6, IL-1beta, IL-1ra, and TGF-alpha mRNA in WT-->WT mice but not in A2A-KO-->WT mice. Plasma creatinine was significantly greater in A2A-KO than in WT mice after IRI, suggesting some renal protection by endogenous adenosine. We conclude that protection from renal IRI by A2AR agonists or endogenous adenosine requires activation of receptors expressed on BM-derived cells.
authors.affiliation: Department of Molecular Physiology and Biological Physics,University of Virginia, Charlottesville, Virginia 22908, USA.
authors.forename: Yuan-Ji
authors.initials: YJ
authors.lastname: Day
authors.forename: Liping
authors.initials: L
authors.lastname: Huang
authors.forename: Marcia J
authors.initials: MJ
authors.lastname: McDuffie
authors.forename: Diane L
authors.initials: DL
authors.lastname: Rosin
authors.forename: Hong
authors.initials: H
authors.lastname: Ye
authors.forename: Jiang-Fan
authors.initials: JF
authors.lastname: Chen
authors.forename: Michael A
authors.initials: MA
authors.lastname: Schwarzschild
authors.forename: J Stephen
authors.initials: JS
authors.lastname: Fink
authors.forename: Joel
authors.initials: J
authors.lastname: Linden
authors.forename: Mark D
authors.initials: MD
authors.lastname: Okusa
mesh_terms: D000241:Adenosine / Q000378:metabolism; D000818:Animals; D001854:Bone Marrow Cells / Q000378:metabolism*; D001921:Brain / Q000166:cytology / Q000378:metabolism; D017690:Cell Transplantation; D018925:Chemokines / Q000235:genetics / Q000378:metabolism; D003509:Cyclohexanecarboxylic Acids / Q000378:metabolism; D016207:Cytokines / Q000235:genetics / Q000378:metabolism; D004730:Endothelium, Vascular / Q000166:cytology / Q000378:metabolism; D005838:Genotype; D049452:Green Fluorescent Proteins; D007668:Kidney / Q000378:metabolism*; D008164:Luminescent Proteins / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010641:Phenotype; D058906:Purinergic P1 Receptor Agonists; D011687:Purines / Q000378:metabolism; D018047:Receptors, Purinergic P1 / Q000235:genetics / Q000378:metabolism*; D015427:Reperfusion Injury / Q000378:metabolism*; D018183:Transplantation Chimera
chemical_list: C431129:ATL 146e; D018925:Chemokines; D003509:Cyclohexanecarboxylic Acids; D016207:Cytokines; D008164:Luminescent Proteins; D058906:Purinergic P1 Receptor Agonists; D011687:Purines; D018047:Receptors, Purinergic P1; D049452:Green Fluorescent Proteins; D000241:Adenosine